Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Myasthenia Gravis Therapeutics market. The report identifies the key trends shaping and driving the global Myasthenia Gravis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myasthenia Gravis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Myasthenia Gravis Therapeutics market. Its scope includes:
The report will enhance your decision making capability. It will allow you to:
Summary
GlobalData, the industry analysis specialist, has released its new report, “Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Myasthenia Gravis Therapeutics market. The report identifies the key trends shaping and driving the global Myasthenia Gravis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myasthenia Gravis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Myasthenia Gravis Therapeutics market. Its scope includes:
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myasthenia Gravis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Myasthenia Gravis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myasthenia Gravis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Myasthenia Gravis Therapeutics market
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Myasthenia Gravis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Myasthenia Gravis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Myasthenia Gravis Therapeutics market landscape? – Identify, understand and capitalize.
Contents
1 TABLE OF CONTENTS1.1 List of Tables
1.2 List of Figures
2 MYASTHENIA GRAVIS THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Pharmacological Testing - There are two types of pharmacological tests
2.5.2 Serological Testing:
2.5.3 Electrophysiological Testing:
2.5.4 Imaging Tests:
2.6 Treatment and Management Pattern
2.6.1 Pharmacological Therapy
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 MYASTHENIA GRAVIS THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Global
3.2 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Global
3.3 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The US
3.4 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The US
3.5 Myasthenia Gravis Therapeutics Market Size (2006-2011) - France
3.6 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - France
3.7 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Germany
3.8 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Germany
3.9 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Italy
3.10 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Italy
3.11 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Spain
3.12 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Spain
3.13 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The UK
3.14 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The UK
3.15 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Japan
3.16 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Myasthenia Gravis Therapeutics Market
3.17.1 Drivers for the Myasthenia Gravis Therapeutics Market
3.17.2 Barriers for the Myasthenia Gravis Therapeutics Market
3.17.3 Opportunity and Unmet Need Analysis
3.18 Key Takeaway
4 MYASTHENIA GRAVIS THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the Myasthenia Gravis Therapeutics Market
4.3.1 Acetylcholinesterase Inhibitor (pyridostigmine)
4.3.2 Steroids (prednisone)
4.3.3 Immunosuppressants
4.3.4 Azathioprine
4.3.5 Cyclosporin A
4.3.6 Mycophenolate Mofetil (MMF)
4.3.7 Venoglobulin-IH
4.4 Key Takeaway
5 MYASTHENIA GRAVIS THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Myasthenia Gravis Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Myasthenia Gravis Therapeutics - Phase III Pipeline
5.3.2 Myasthenia Gravis Therapeutics - Phase II Pipeline
5.3.3 Myasthenia Gravis Therapeutics - IND filed Pipeline
5.3.4 Technology Trends Analytic Framework
5.4 Myasthenia Gravis Therapeutics Market -Pipeline by Mechanism of Action
5.5 Myasthenia Gravis Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.7 Key Takeaway
6 MYASTHENIA GRAVIS THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Myasthenia Gravis Therapeutics Clinical Trials
7 STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Myasthenia gravis Therapeutics: Implications for Future Market Competition
8 MYASTHENIA GRAVIS THERAPEUTICS - FUTURE PLAYERS
8.1 Company Profiles
8.2 Cytokinetics, Inc.
8.3 Alexion Pharmaceuticals, Inc
9 MYASTHENIA GRAVIS THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS
10 MYASTHENIA GRAVIS THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
LIST OF TABLES
Table 1: Clinical Classification of Myasthenia Gravis According to Myasthenia Gravis Foundation of America (MGFA)
Table 2: Prevalence of Myasthenia Gravis by Country (G7)
Table 3: Myasthenia Gravis Quality of Life Questionnaire
Table 4: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 5: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 6: Myasthenia Gravis Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 7: Myasthenia Gravis Therapeutics Market, The US, Forecasts ($m), 2011-2019
Table 8: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011
Table 9: Myasthenia Gravis Therapeutics Market, France, Forecasts ($m), 2011-2019
Table 10: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 11: Myasthenia Gravis Therapeutics Market, Germany, Forecasts ($m), 2011-2019
Table 12: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 13: Myasthenia Gravis Therapeutics Market, Italy, Forecasts ($m), 2011-2019
Table 14: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 15: Myasthenia Gravis Therapeutics Market, Spain, Forecasts ($m), 2011-2019
Table 16: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 17: Myasthenia Gravis Therapeutics Market, The UK, Forecasts ($m), 2011-2019
Table 18: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 19: Myasthenia Gravis Therapeutics Market, Japan, Forecasts ($m), 2011-2019
Table 20: Myasthenia gravis Therapeutics, Phase III Pipeline, 2011
Table 21: Myasthenia gravis Therapeutics, Phase II Pipeline, 2011
Table 22: Myasthenia Gravis Therapeutics, IND Filed Pipeline, 2011
Table 23: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011
Table 24: Myasthenia Gravis Therapeutics, Clinical Trials by Phase, 2011
Table 25: Myasthenia Gravis Therapeutics, Clinical Trials by Status, 2011
Table 26: Myasthenia Gravis Therapeutics, Prominent Sponsors, 2011
Table 27: Myasthenia Gravis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 28: Cytokinetics, Inc., Pipeline, 2011
Table 29: Alexion Pharmaceuticals, Inc., Pipeline, 2011
LIST OF FIGURES
Figure 1: Normal Neuromuscular Junction
Figure 2: Difference Between Normal and Myasthenic Neuromuscular Junctions
Figure 3: Signs and Symptoms
Figure 4: Repetitive Nerve Stimulation Electrical Tracing
Figure 5: Referral Pathway
Figure 6: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 7: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 8: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2006-2011
Figure 9: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 10: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 11: Myasthenia Gravis Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 12: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 13: Myasthenia Gravis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 14: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 15: Myasthenia Gravis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 16: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 17: Myasthenia Gravis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 18: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 19: Myasthenia Gravis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 20: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 21: Myasthenia Gravis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 22: Opportunity and Unmet Need in the Myasthenia Gravis Therapeutics Market, 2011
Figure 23: Myasthenia Gravis Therapeutics, Strategic Competitor Assessment, 2010
Figure 24: Myasthenia gravis Therapeutics - Pipeline by Phase of Development, 2011
Figure 25: Myasthenia Gravis Therapeutics, Technology Trends Analytics Framework, 2011
Figure 26: Myasthenia Gravis Pipeline, Technology Trends Analytics Framework, Description, 2011
Figure 27: Myasthenia Gravis Therapeutics, Pipeline by Mechanism of Action, 2011
Figure 28: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011
Figure 29: Myasthenia Gravis Therapeutics, Clinical Trials by Phase (%), 2011
Figure 30: Myasthenia Gravis Therapeutics, Clinical Trials by Status (%), 2011
Figure 31: Myasthenia Gravis Therapeutics, Overall Sponsors (%), 2011
Figure 32: Myasthenia Gravis Therapeutics, Prominent Sponsors (%), 2011
Figure 33: Myasthenia Gravis Therapeutics Market, Drivers and Restraints, 2011
Figure 34: Implications for Future Market Competition in the Myasthenia Gravis Therapeutics Market, 2011
Figure 35: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Cytokinetics, Inc.
Alexion Pharmaceuticals, Inc Skip to top